The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development

With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.

What are incretins and how do they really work? How can we better understand their effects and advance drug development in obesity and metabolic disease? What will the future of incretin-based drug development look like?

It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know. In this webinar, the expert speakers will cover how incretins were discovered, what we know about them, current challenges facing incretin drug development and some of the exciting work that is ongoing in this space. They will also discuss how advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can give us insights that will help us to better understand incretins, as well as provide relevant information for future drug development.

Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers’ perspectives on the future of incretin drug development.

Speakers

Tina Vilsbøll, MD, DMSc, Professor at Steno Diabetes Centre Copenhagen, University of Copenhagen, Denmark

Tina Vilsbøll has been involved in clinical research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark. She is now the Research Leader of Cardio-Metabolic Prevention and consultant at Steno Diabetes Center Copenhagen, Denmark. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake and the utilization of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. Tina is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She has more than 450 scientific publications (H-index 83), several published books and book chapters. She is currently the Honorary Secretary and board member of the European Association for the Study of Diabetes (EASD) and is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Tina is a member of numerous professional societies and committees, and referees for several international journals.

Message Presenter

Michael Wagner, Senior Vice President, Chemistry and Drug Discovery, Dewpoint Therapeutics; Co-Founder, Antaros Tracer

Michael Wagner is a biotech entrepreneur and is currently Senior Vice President, Chemistry and Drug Discovery, at Dewpoint Therapeutics, a biotech company exploring biomolecular condensates. Before joining Dewpoint, Michael helped to found Antaros Tracer, a company developing new tracers for PET imaging. Prior to this, he was leading the Synthetic Medicinal Modalities Department at Sanofi, overseeing the small molecule portfolio, peptide drug discovery, proteins & conjugates and new delivery technologies for sustained, oral and smart delivery of biomolecules. His scientific contributions have resulted in more than 15 clinical development candidates and over 80 patents or peer-reviewed publications. Michael is currently an advisor to several early-stage biotech companies, has served on numerous scientific advisory boards and is active in various professional societies for the advancement of chemical sciences and peptide sciences. Michael holds a PhD in organic & bioorganic chemistry from the University of Mainz, Germany.

Message Presenter

Martin Schain, Director of PET Imaging, Antaros Medical

Martin Schain is an expert in PET imaging with a particular focus on imaging of the brain as well as quantitative aspects of PET data analysis. In 2013, Martin completed his PhD at Karolinska Institutet (Stockholm, Sweden) and has conducted postdoctoral research at Columbia University (New York City, NY, USA) and Copenhagen University Hospital (Copenhagen, Denmark). He has been awarded several prestigious recognitions for his scientific merits, including the NARSAD Young Investigator Award and the Marie Sklodowska-Curie fellowship. Since 2021, Martin has been a Director of PET imaging at Antaros Medical, where he oversees clinical trials that utilize PET-derived endpoints.

Message Presenter